Preparation method of fenoprofen
Finoprofen is directly produced through C-O coupling and subsequent reaction of 3-hydroxyacetophenone and bromobenzene, which solves the problems of high cost and low yield in the existing technology, and achieves efficient and safe Finolo Prepared for fin, suitable for industrial production.
Patent Information
- Application Number
- CN202411057027.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-22
AI Technical Summary
The existing Finoprofen preparation method has high cost, poor safety and low yield, making it difficult to be suitable for large-scale industrial production.
C-O coupling is carried out under the action of cuprous halide by 3-hydroxyacetophenone and bromobenzene to form aryl ether intermediate I, and then react with halogenated acetate derivatives through Dacuns condensation, ester bond hydrolysis, and decarboxylation. , forming Intermediate II, and undergoing oxilation and hydrolysis reaction with hydroxylamine hydrochloride under alkali action, to directly produce fenoprofen, without purification operations in the whole process, simplifying the process flow.
It achieves high yield (greater than 70%) and high purity production of finoprofen, reduces production costs, is suitable for industrial production, and is easy to operate.
Smart Images

Figure CN118993870A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceutical chemistry and relates to a preparation method of fenoprofen. Background Art
[0002] Fenoprofen, chemical name 2-[3-(phenoxy)phenyl]propionic acid, has the following chemical structure:
[0003]
[0004] Fenoprofen is an aromatic propionic acid nonsteroidal anti-inflammatory drug with a wide range of clinical applications, mainly for the treatment of rheumatoid arthritis and osteoarthritis. Summary of the invention
[0005] The technical problem to be solved by the present invention is to provide a preparation method of fenoprofen in view of the deficiencies in the prior art. The method has low reaction cost, good safety, high yield and high reaction efficiency and is suitable for large-scale industrial production.
[0006] Invention idea: The present invention provides a preparation method of fenoprofen, which uses 3-hydroxyacetophenone and bromobenzene as raw materials, and undergoes CO coupling under the action of cuprous halide to generate an aromatic ether intermediate I; intermediate I and a halogenated acetic acid ester derivative undergo Tacunci condensation, ester bond hydrolysis, and decarboxylation to obtain intermediate II; intermediate II and hydroxylamine hydrochloride undergo oximation reaction and hydrolysis reaction to obtain fenoprofen; the preparation method provided by the present invention obtains fenoprofen through three-step reaction, and after each step of the reaction is completed, no purification operation is required, and fenoprofen can be obtained with high yield and high purity through simple extraction post-treatment operation, and the total yield is greater than 70%. The synthesis process provided by the present invention has low production cost, high yield of target product, simple operation, and is suitable for industrial production.
[0007] In order to solve the above technical problems, the technical solution adopted by the present invention is as follows:
[0008] The present invention provides a method for preparing fenoprofen. An intermediate II and hydroxylamine hydrochloride undergo an oximation reaction under the action of a base E, and then undergo a hydrolysis reaction under the action of a base F to obtain fenoprofen.
[0009]
[0010] In some embodiments, the molar ratio of the intermediate II to hydroxylamine hydrochloride is 1:1.0-3.0, preferably 1:1.2-2.0, and more preferably 1:1.5-1.8; the base E is sodium carbonate, potassium carbonate or cesium carbonate, preferably sodium carbonate; the molar ratio of the intermediate II to the base E is 1:1.0-3.0, preferably 1:1.2-2.0, and more preferably 1:1.5-1.8; the oximation reaction, the reaction temperature is 15-35 ° C, preferably The temperature is selected to be 18-35°C, and more preferably 20-30°C; the base F is any one of sodium hydroxide and potassium hydroxide or a combination of two, preferably potassium hydroxide; the molar ratio of the intermediate II to the base F is 1:5.0-10.0, preferably 1:6.0-9.0, and more preferably 1:7.0-8.0; the hydrolysis reaction has a reaction temperature of 105-125°C, and preferably 110-120°C; the hydrolysis reaction is carried out under the protection of an inert gas.
[0011] In some embodiments, the fifth solvent used in the oximation reaction is water; the base F exists in the form of a solution, and the base F is mixed with water to prepare a base F solution.
[0012] Specifically, there is no special requirement for the fifth solvent, as long as it can dissolve the raw materials and the viscosity of the reaction system is moderate.
[0013] Specifically, after the oximation reaction is completed, ethyl acetate is added to the reaction solution and mixed, and the mixture is allowed to stand for separation, and the organic phase is retained; ethyl acetate is added to the aqueous phase and mixed, and the mixture is allowed to stand for separation, and the organic phase is retained; the organic phases are combined, concentrated to dryness under reduced pressure, and an alkali F solution is added to the concentrate for hydrolysis reaction.
[0014] Specifically, the mass concentration of alkali F in the alkali F solution is 40% to 60%, preferably 45% to 55%, and more preferably 50%.
[0015] Specifically, the inert gas is preferably nitrogen.
[0016] Specifically, after the hydrolysis reaction is completed, the reaction solution is cooled to 20-30°C, the reaction solution is extracted with ethyl acetate several times, and the aqueous phase is retained; the pH of the aqueous phase is adjusted to 6.0-7.0 with a dilute hydrochloric acid aqueous solution, ethyl acetate is added to the reaction solution and mixed, the mixture is allowed to stand and the organic phase is retained; the organic phase is washed with saturated brine, and the organic phase is concentrated to dryness to obtain fenoprofen; wherein the concentration of the dilute hydrochloric acid aqueous solution is preferably 3-6 mol / L, preferably 3-5 mol / L, and more preferably 4 mol / L.
[0017] Specifically, the intermediate II can be purchased commercially, or prepared according to the prior art, or prepared according to the following method:
[0018] Intermediate I undergoes Darwin condensation reaction with a halogenated acetic acid ester derivative under the action of base C, and then undergoes ester bond hydrolysis reaction under the action of base D, and then undergoes decarboxylation reaction under the action of acid B to obtain intermediate II;
[0019]
[0020] Wherein, R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl; X is selected from Br or Cl.
[0021] The intermediate I can be purchased commercially, prepared according to the prior art, or prepared according to the following method:
[0022] 3-Hydroxyacetophenone and bromobenzene undergo a substitution reaction under the action of a catalyst, a base A, and a ligand to obtain an intermediate I;
[0023]
[0024] Furthermore, the present invention provides a method for preparing fenoprofen, comprising the following steps:
[0025] (I) 3-Hydroxyacetophenone and bromobenzene undergo a substitution reaction under the action of a catalyst, a base A, and a ligand to obtain an intermediate I;
[0026]
[0027] (II) Intermediate I and a halogenated acetic acid ester derivative undergo a Darwin condensation reaction under the action of a base C, and then undergo an ester bond hydrolysis reaction under the action of a base D, and then undergo a decarboxylation reaction under the action of an acid B to obtain an intermediate II;
[0028]
[0029] (III) Intermediate II undergoes an oximation reaction with hydroxylamine hydrochloride under the action of base E, and then undergoes a hydrolysis reaction under the action of base F to obtain fenoprofen;
[0030]
[0031] Wherein, R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl; X is selected from Br or Cl.
[0032] In some embodiments, in step (I), the molar ratio of 3-hydroxyacetophenone to bromobenzene is 1:0.8-1.2, preferably 1:0.90-1.1, and more preferably 1:0.95-1.0; the catalyst is cuprous chloride, cuprous bromide or cuprous iodide, preferably cuprous iodide; the base A is sodium carbonate, potassium carbonate or cesium carbonate, preferably cesium carbonate; the ligand is 8-hydroxyquinoline, 1,10-phenanthroline, 2-aminopyridine, 2,2'-bipyridylamine, preferably 2,2'-bipyridylamine; the 3 The molar ratio of 3-hydroxyacetophenone to the catalyst is 1: 0.05-0.2, preferably 1: 0.1-0.15; the molar ratio of the 3-hydroxyacetophenone to the base A is 1: 1.5-3.0, preferably 1: 2.0-2.5; the molar ratio of the 3-hydroxyacetophenone to the ligand is 1: 0.1-0.4, preferably 1: 0.2-0.3; the reaction temperature of the substitution reaction is 80-140° C., preferably 90-120° C., and more preferably 100-110° C.; the substitution reaction is carried out under the protection of an inert gas.
[0033] In some embodiments, in step (I), the inert gas is nitrogen or argon.
[0034] In some embodiments, in step (I), the first solvent used in the substitution reaction is dimethyl sulfoxide, NN-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, preferably 1,4-dioxane; after the substitution reaction is completed, the reaction solution is filtered, the filter cake is washed with a second solvent, and the filtrate is washed with an alkali B solution and an acid A solution; the second solvent is ethyl acetate, isopropyl acetate, dichloromethane, methyl tert-butyl ether, n-heptane, preferably ethyl acetate; the alkali B solution is a sodium hydroxide solution; the acid A solution is a hydrochloric acid solution.
[0035] Specifically, in step (I), there is no special requirement for the amount of the first solvent, as long as the raw materials are dissolved and the viscosity of the reaction system is moderate; the amount of the second solvent is preferably the same as the amount of the first solvent; the amount of the base B solution is preferably 1 to 2 times the amount of the first solvent, and more preferably 4 / 3 times; the amount of the acid A solution is preferably 1 to 2 times the amount of the first solvent, and more preferably 4 / 3 times.
[0036] Specifically, in step (I), when the alkali B solution is a sodium hydroxide solution, the solvent in the sodium hydroxide solution is water, and the concentration of sodium hydroxide is 0.5 to 2 mol / L, preferably 1 mol / L; when the acid A solution is a hydrochloric acid solution, the solvent in the hydrochloric acid solution is water, and the concentration of hydrochloric acid is 0.5 to 2 mol / L, preferably 1 mol / L.
[0037] In some embodiments, in step (II), the halogenated acetate derivative is ethyl chloroacetate, methyl chloroacetate, n-propyl chloroacetate, isopropyl chloroacetate, n-butyl chloroacetate or tert-butyl chloroacetate, preferably ethyl chloroacetate; the molar ratio of the intermediate I to the halogenated acetate derivative is 1:1.0-1.5, preferably 1:1.1-1.4, and more preferably 1:1.2-1.3; the base C is any one or a combination of two of sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, sodium isopropoxide, potassium isopropoxide, sodium tert-butoxide and potassium tert-butoxide, preferably sodium ethoxide; the molar ratio of the intermediate I to the base C is 1:1.0-1.5, preferably 1:1.1-1.4, and more preferably 1:1.2-1.3; the Darcun condensation reaction The reaction temperature is 0-35°C, preferably 0-30°C; the Darcuns condensation reaction is carried out under the protection of inert gas; the base D is any one of sodium hydroxide and potassium hydroxide or a combination of two, preferably sodium hydroxide; the molar ratio of the intermediate I to the base D is 1:1.0-1.5, preferably 1:1.1-1.4, and more preferably 1:1.2-1.3; the reaction temperature of the ester bond hydrolysis reaction is 25-45°C, preferably 30-40°C; the acid B is concentrated hydrochloric acid or concentrated sulfuric acid, preferably concentrated hydrochloric acid; the molar ratio of the intermediate I to the acid B is 1:1.2-2.0, preferably 1:1.3-1.8, and more preferably 1:1.5-1.6; the reaction temperature of the decarboxylation reaction is 80-100°C, preferably 85-95°C.
[0038] In some embodiments, in step (II), the third solvent used in the Darwin condensation reaction is any one or a combination of toluene, ethyl acetate, isopropyl acetate, dichloromethane and methyl tert-butyl ether, preferably toluene; the base C exists in the form of a solution, and the base C is mixed with the fourth solvent to obtain a base C solution; the base D exists in the form of a solution, and the base D is mixed with water to obtain a base D solution; the acid B exists in the form of a solution, and the acid B is mixed with water to obtain an acid B solution; the fourth solvent is any one or a combination of anhydrous methanol, anhydrous ethanol, anhydrous isopropanol and anhydrous tert-butyl alcohol, preferably anhydrous ethanol.
[0039] Specifically, in step (II), there is no special requirement for the amount of the third solvent, as long as the raw materials are dissolved and the viscosity of the reaction system is moderate; the mass concentration of alkali C in the alkali C solution is 20-40%, preferably 20-30%, and more preferably 24%-25%; the Darcuns condensation reaction is carried out at 0-10°C for 0.8-1.2h, and then slowly heated to 20-30°C and continued to react for 5-7h; the Darcuns condensation reaction is carried out under nitrogen protection; the mass concentration of alkali D in the alkali D solution is 25%-40%, preferably 28%-35%.
[0040] Specifically, in step (II), after the ester bond hydrolysis reaction is completed, the reaction solution is allowed to stand for separation, and the aqueous phase is retained; a third solvent is added to the aqueous phase and mixed, and the solution is allowed to stand for separation, and the aqueous phase is retained; a third solvent is added to the aqueous phase and mixed, and then acid B is added for decarboxylation reaction.
[0041] Specifically, in step (II), the mass concentration of acid B in the acid B solution is 35% to 38%, preferably 37% to 38%.
[0042] Specifically, in step (II), after the decarboxylation reaction is completed, the temperature is lowered to 20-30° C., the liquids are separated, and the organic phase is retained; the organic phase is washed with saturated brine, and the organic phase is concentrated to dryness to obtain intermediate II, which is directly used in the next reaction without purification.
[0043] In some embodiments, in step (III), the molar ratio of the intermediate II to hydroxylamine hydrochloride is 1:1.0-3.0, preferably 1:1.2-2.0, and more preferably 1:1.5-1.8; the base E is sodium carbonate, potassium carbonate or cesium carbonate, preferably sodium carbonate; the molar ratio of the intermediate II to the base E is 1:1.0-3.0, preferably 1:1.2-2.0, and more preferably 1:1.5-1.8; the oximation reaction, the reaction temperature is 15- 35°C, preferably 18-35°C, more preferably 20-30°C; the base F is any one of sodium hydroxide and potassium hydroxide or a combination of two, preferably potassium hydroxide; the molar ratio of the intermediate II to the base F is 1:5.0-10.0, preferably 1:6.0-9.0, more preferably 1:7.0-8.0; the hydrolysis reaction, the reaction temperature is 105-125°C, preferably 110-120°C; the hydrolysis reaction is carried out under the protection of an inert gas.
[0044] In some embodiments, in step (III), the fifth solvent used in the oximation reaction is water; the base F exists in the form of a solution, and the base F is mixed with water to prepare a base F solution.
[0045] Specifically, in step (III), there is no special requirement for the fifth solvent, as long as it can dissolve the raw materials and the viscosity of the reaction system is moderate.
[0046] Specifically, in step (III), after the oximation reaction is completed, ethyl acetate is added to the reaction solution and mixed, and the mixture is allowed to stand for separation, and the organic phase is retained; ethyl acetate is added to the aqueous phase and mixed, and the mixture is allowed to stand for separation, and the organic phase is retained; the organic phases are combined, concentrated to dryness under reduced pressure, and an alkali F solution is added to the concentrate for hydrolysis reaction.
[0047] Specifically, in step (III), the mass concentration of alkali F in the alkali F solution is 40% to 60%, preferably 45% to 55%, and more preferably 50%.
[0048] Specifically, in step (III), the inert gas is preferably nitrogen.
[0049] Specifically, in step (III), after the hydrolysis reaction is completed, the reaction solution is cooled to 20-30° C., the reaction solution is extracted with ethyl acetate several times, and the aqueous phase is retained; the pH of the aqueous phase is adjusted to 6.0-7.0 with a dilute hydrochloric acid aqueous solution, ethyl acetate is added to the reaction solution and mixed, the mixture is allowed to stand for separation, and the organic phase is retained; the organic phase is washed with saturated brine, and the organic phase is concentrated to dryness to obtain fenoprofen; wherein the concentration of the dilute hydrochloric acid aqueous solution is preferably 3-6 mol / L, preferably 3-5 mol / L, and more preferably 4 mol / L.
[0050] Furthermore, the present invention provides a method for preparing intermediate I, wherein 3-hydroxyacetophenone and bromobenzene undergo a substitution reaction under the action of a catalyst, a base A, and a ligand to prepare intermediate I;
[0051]
[0052] In some embodiments, the molar ratio of 3-hydroxyacetophenone to bromobenzene is 1:0.8-1.2, preferably 1:0.90-1.1, and further preferably 1:0.95-1.0; the catalyst is cuprous chloride, cuprous bromide or cuprous iodide, preferably cuprous iodide; the base A is sodium carbonate, potassium carbonate or cesium carbonate, preferably cesium carbonate; the ligand is 8-hydroxyquinoline, 1,10-phenanthroline, 2-aminopyridine, 2,2'-bipyridylamine, preferably 2,2'-bipyridylamine; the 3-hydroxybenzene The molar ratio of acetone to catalyst is 1:0.05-0.2, preferably 1:0.1-0.15; the molar ratio of 3-hydroxyacetophenone to base A is 1:1.5-3.0, preferably 1:2.0-2.5; the molar ratio of 3-hydroxyacetophenone to ligand is 1:0.1-0.4, preferably 1:0.2-0.3; the reaction temperature of the substitution reaction is 80-140°C, preferably 90-120°C, and more preferably 100-110°C; the substitution reaction is carried out under the protection of inert gas.
[0053] In some embodiments, the inert gas is nitrogen or argon.
[0054] In some embodiments, the first solvent used in the substitution reaction is dimethyl sulfoxide, NN-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, preferably 1,4-dioxane; after the substitution reaction is completed, the reaction solution is filtered, the filter cake is washed with a second solvent, and the filtrate is washed with an alkali B solution and an acid A solution; the second solvent is ethyl acetate, isopropyl acetate, dichloromethane, methyl tert-butyl ether, n-heptane, preferably ethyl acetate; the alkali B solution is a sodium hydroxide solution; the acid A solution is a hydrochloric acid solution.
[0055] Specifically, in step (I), there is no special requirement for the amount of the first solvent, as long as the raw materials are dissolved and the viscosity of the reaction system is moderate; the amount of the second solvent is preferably the same as the amount of the first solvent; the amount of the base B solution is preferably 1 to 2 times the amount of the first solvent, and more preferably 4 / 3 times; the amount of the acid A solution is preferably 1 to 2 times the amount of the first solvent, and more preferably 4 / 3 times.
[0056] Specifically, in step (I), when the alkali B solution is a sodium hydroxide solution, the solvent in the sodium hydroxide solution is water, and the concentration of sodium hydroxide is 0.5 to 2 mol / L, preferably 1 mol / L; when the acid A solution is a hydrochloric acid solution, the solvent in the hydrochloric acid solution is water, and the concentration of hydrochloric acid is 0.5 to 2 mol / L, preferably 1 mol / L.
[0057] Furthermore, the present invention provides a method for preparing intermediate II, wherein intermediate I and a halogenated acetic acid ester derivative undergo a Darwin condensation reaction under the action of a base C, and then undergo an ester bond hydrolysis reaction under the action of a base D, and then undergo a decarboxylation reaction under the action of an acid B to obtain intermediate II;
[0058]
[0059] Wherein, R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl; X is selected from Br or Cl.
[0060] In some embodiments, the halogenated acetate derivative is ethyl chloroacetate, methyl chloroacetate, n-propyl chloroacetate, isopropyl chloroacetate, n-butyl chloroacetate or tert-butyl chloroacetate, preferably ethyl chloroacetate; the molar ratio of the intermediate I to the halogenated acetate derivative is 1:1.0-1.5, preferably 1:1.1-1.4, and more preferably 1:1.2-1.3; the base C is any one or a combination of two of sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, sodium isopropoxide, potassium isopropoxide, sodium tert-butoxide and potassium tert-butoxide, preferably sodium ethoxide; the molar ratio of the intermediate I to the base C is 1:1.0-1.5, preferably 1:1.1-1.4, and more preferably 1:1.2-1.3; the Darcun condensation reaction, the reaction The temperature is 0-35°C, preferably 0-30°C; the Darcuns condensation reaction is carried out under the protection of inert gas; the base D is any one of sodium hydroxide and potassium hydroxide or a combination of two, preferably sodium hydroxide; the molar ratio of the intermediate I to the base D is 1:1.0-1.5, preferably 1:1.1-1.4, and more preferably 1:1.2-1.3; the reaction temperature of the ester bond hydrolysis reaction is 25-45°C, preferably 30-40°C; the acid B is concentrated hydrochloric acid or concentrated sulfuric acid, preferably concentrated hydrochloric acid; the molar ratio of the intermediate I to the acid B is 1:1.2-2.0, preferably 1:1.3-1.8, and more preferably 1:1.5-1.6; the reaction temperature of the decarboxylation reaction is 80-100°C, preferably 85-95°C.
[0061] In some embodiments, the third solvent used in the Darcuns condensation reaction is any one or a combination of toluene, ethyl acetate, isopropyl acetate, dichloromethane and methyl tert-butyl ether, preferably toluene; the base C exists in the form of a solution, and the base C is mixed with the fourth solvent to obtain a base C solution; the base D exists in the form of a solution, and the base D is mixed with water to obtain a base D solution; the acid B exists in the form of a solution, and the acid B is mixed with water to obtain an acid B solution; the fourth solvent is any one or a combination of anhydrous methanol, anhydrous ethanol, anhydrous isopropanol and anhydrous tert-butyl alcohol, preferably anhydrous ethanol.
[0062] Specifically, there is no special requirement for the amount of the third solvent, as long as the raw materials are dissolved and the viscosity of the reaction system is moderate; the mass concentration of alkali C in the alkali C solution is 20-40%, preferably 20-30%, and more preferably 24%-25%; the Darcuns condensation reaction is carried out at 0-10°C for 0.8-1.2h, and then slowly heated to 20-30°C and continued to react for 5-7h; the Darcuns condensation reaction is carried out under nitrogen protection; the mass concentration of alkali D in the alkali D solution is 25%-40%, preferably 28%-35%.
[0063] Specifically, after the ester bond hydrolysis reaction is completed, the reaction solution is allowed to stand for separation, and the aqueous phase is retained; the third solvent is added to the aqueous phase for mixing, and the solution is allowed to stand for separation, and the aqueous phase is retained; the third solvent is added to the aqueous phase for mixing, and then acid B is added for decarboxylation reaction.
[0064] Specifically, the mass concentration of acid B in the acid B solution is 35% to 38%, preferably 37% to 38%.
[0065] Specifically, after the decarboxylation reaction is completed, the temperature is lowered to 20-30° C., the liquids are separated, and the organic phase is retained; the organic phase is washed with saturated brine, and the organic phase is concentrated to dryness to obtain intermediate II, which is directly used in the next reaction without purification.
[0066] Furthermore, the present invention provides a method for preparing fenoprofen, comprising the steps shown in the following route:
[0067]
[0068] Wherein, R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl; X is selected from Br or Cl.
[0069] Beneficial effects:
[0070] (1) Compared with the prior art, the synthesis process provided by the present invention has the advantages of low production cost, high yield of target product, simple operation and suitability for industrial production.
[0071] (2) Compared with the prior art, the synthesis process provided by the present invention can obtain Fenoprofen through three-step reaction. After each step of the reaction, no purification operation is required. Fenoprofen can be obtained with high yield and high purity through simple extraction and post-treatment operation, and the total yield is greater than 70%. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.
[0073] Figure 1 : H NMR spectrum of intermediate I obtained in Example 1;
[0074] Figure 2 : NMR carbon spectrum of intermediate I obtained in Example 1;
[0075] Figure 3 : Mass spectrum of intermediate I obtained in Example 1;
[0076] Figure 4 : H NMR spectrum of intermediate II obtained in Example 1;
[0077] Figure 5: The H NMR spectrum of Fenoprofen obtained in Example 1;
[0078] Figure 6 : The NMR carbon spectrum of Fenoprofen obtained in Example 1;
[0079] Figure 7 : Mass spectrum of Fenoprofen obtained in Example 1. DETAILED DESCRIPTION
[0080] The present invention will be described in more detail below through examples. These examples are used for further explanation and can better understand the content of the present invention, but should not be regarded as limiting the present invention.
[0081] The term "controlling the internal temperature" in the embodiments of the present invention refers to the internal temperature of the reaction.
[0082] In the embodiments of the present invention, the concentrations expressed in % are all mass percentages unless otherwise specified.
[0083] Embodiment 1:
[0084] (1) Synthesis of intermediate I:
[0085]
[0086] 3-Hydroxyacetophenone (5.0 g, 36.7 mmol), bromobenzene (5.77 g, 36.7 mmol), cuprous iodide (0.70 g, 3.76 mmol), cesium carbonate (23.93 g, 73.44 mmol), 2,2'-bipyridylamine (1.26 g, 7.36 mmol), 1,4-dioxane (75 mL) were added to a 250 mL three-necked flask, and the atmosphere was replaced with nitrogen. The substitution reaction was carried out at 105±5° C. with stirring for 26 h. After the reaction was completed, the mixture was filtered, and the filter cake was rinsed with ethyl acetate (75 mL). The filtrate was washed with 1 mol / L sodium hydroxide aqueous solution (100 mL), 1 mol / L hydrochloric acid aqueous solution (100 mL), and saturated brine (100 mL) in sequence. The organic phase was concentrated under reduced pressure to obtain 7.09 g (yield of about 91%) of yellow oily intermediate I with a purity of 93%.
[0087] 1 H NMR (400MHz, d6-DMSO): δ7.76 (d, 1H), δ7.55 (t, 1H), δ7.49 (d, 1H), δ7.45 (t, 2H), δ7.29 (m, 1H), δ7.20 (t, 1H), δ7.06 (dd, 2H), δ2.50 (s, 3H). The H NMR spectrum of intermediate I is shown in Figure 1 .
[0088] 13C-NMR (100MHz, d6-DMSO): δ197.8, δ157.6, δ156.5, δ139.1, δ131.0, δ130.7, δ124.5, δ123.9, δ123.6, δ119.5, δ117.5, δ27.3, the NMR carbon spectrum of intermediate I is shown in Figure 2 .
[0089] MS (m / z): 213.0 [M+H] + The mass spectrum of intermediate I is shown in Figure 3 .
[0090] (2) Synthesis of Intermediate II:
[0091]
[0092] Wherein, R1 is selected from ethyl.
[0093] Add intermediate I (5.0 g, 23.6 mmol), toluene (15 mL), and ethyl chloroacetate (3.47 g, 28.3 mmol) to a 100 mL three-necked flask, replace with nitrogen, and cool to 0-10°C; weigh sodium ethoxide (1.92 g, 28.3 mmol) and dissolve it in anhydrous ethanol (7.5 mL) to obtain a sodium ethoxide solution; drip the sodium ethoxide solution into the reaction solution while controlling the temperature of the reaction solution to 0-10°C, continue stirring at 0-10°C for 1 h after dripping, slowly heat to 20-30°C, stir and react for 6 h, add toluene (15 mL) and stir after the reaction is completed; slowly drip a NaOH aqueous solution (1.13 g hydroxyethyl ether) into the reaction solution; Sodium hydroxide was dissolved in 2.5 mL of water), and after the addition, the temperature was raised to 30-40°C and stirring was continued for 1 h; after the reaction was completed, stirring was stopped, the liquid was allowed to stand for separation, and the aqueous phase was retained; 30 mL of toluene was added to the aqueous phase and stirred for 15-20 min, stirring was stopped, the liquid was allowed to stand for separation, and the aqueous phase was retained; 30 mL of toluene was added to the aqueous phase and stirred, concentrated hydrochloric acid (2.95 mL, 37 wt%, 35.3 mmol) was slowly added, and the temperature was raised to 85-95°C and stirred for 4 h; after the reaction was completed, the temperature was lowered to 20-30°C, the liquid was separated, and the organic phase was retained; the organic phase was washed with saturated brine (30 mL) and saturated brine (30 mL), respectively, and the organic phase was concentrated to dryness to obtain 4.69 g of light yellow oily intermediate II (yield of about 88%, directly used in the next step reaction) with a purity of 93%.
[0094] 1 H NMR (400MHz, d6-DMSO): δ9.70 (s, 1H), δ7.37 (m, 3H), δ7.15 (t, 1H), δ7.04 (d, 2H), δ6.95 (m, 3H), δ3.63 (q, 1H), δ1.45 (d, 3H). The H NMR spectrum of intermediate II is shown in Figure 4 .
[0095] (3) Synthesis of Fenoprofen:
[0096]
[0097] Add intermediate II (5.0 g, 22.1 mmol), hydroxylamine hydrochloride (2.30 g, 33.1 mmol), sodium carbonate (3.51 g, 33.1 mmol) and 50 mL of water to a 100 mL three-necked flask and stir at 20-30 °C for 2 h; after the reaction is completed, add ethyl acetate (30 mL) to the reaction solution, stir for 15-20 min, stop stirring, stand for separation, and retain the organic phase; add ethyl acetate (30 mL) to the aqueous phase, stir for 15-20 min, stop stirring, stand for separation, and retain the organic phase; combine the organic phases, concentrate to dryness under reduced pressure, and add potassium hydroxide aqueous solution (9. 30g potassium hydroxide is dissolved in 9.3mL water), after nitrogen replacement, the temperature is raised to 110-120°C and stirred for reaction for 8h; the temperature is lowered to 20-30°C, the reaction solution is extracted with ethyl acetate 3 times (30mL×3), and the aqueous phase is retained; the pH of the aqueous phase is adjusted to 6.0-7.0 with 4mol / L dilute hydrochloric acid, 30mL ethyl acetate is added to the reaction solution, stirred for 15-20min, the stirring is stopped, the liquid is allowed to stand, and the organic phase is retained; the organic phase is washed with saturated brine (30mL) and saturated brine (30mL), respectively, and the organic phase is concentrated to dryness to obtain 4.76g of light yellow oily fenoprofen (yield of about 89%) with a purity of 95%.
[0098] 1 H NMR (400MHz, d6-DMSO): δ12.36 (s, 1H), δ7.40 (m, 2H), δ7.33 (t, 1H), δ7.15 (t, 1H), δ7.05 (d, 1H), δ7.01 (dd, 2H), δ6.95 (dd, 1H), δ6.86 (m, 1H), δ3.67 (q, 1H), δ1.34 (d, 3H). See the H NMR spectrum of fenoprofen. Figure 5 .
[0099] 13 C-NMR (100MHz, d6-DMSO): δ175.5, δ157.2, δ156.9, δ143.9, δ130.5, δ130.4, δ124.0, δ122.9, δ119.2, δ118.1, δ117.2, δ44.9, δ18.9, see the NMR carbon spectrum of fenoprofen Figure 6 .
[0100] MS(m / z):241.1[MH] + , the mass spectrum of fenoprofen is shown in Figure 7 .
[0101] Example 2
[0102] (1) Synthesis of intermediate I:
[0103]
[0104] 3-Hydroxyacetophenone (5.0 g, 36.7 mmol), bromobenzene (4.60 g, 29.4 mmol), cuprous iodide (1.05 g, 5.64 mmol), cesium carbonate (29.9 g, 91.8 mmol), 2,2'-bipyridylamine (1.89 g, 11.04 mmol), 1,4-dioxane (75 mL) were added to a 250 mL three-necked flask, and the atmosphere was replaced with nitrogen. The substitution reaction was carried out at 95±5° C. with stirring for 30 h. After the reaction was completed, the mixture was filtered, and the filter cake was rinsed with ethyl acetate (75 mL). The filtrate was washed with 1 mol / L sodium hydroxide aqueous solution (100 mL), 1 mol / L hydrochloric acid aqueous solution (100 mL), and saturated brine (100 mL) in sequence. The organic phase was concentrated under reduced pressure to obtain 7.01 g (yield of about 90%) of yellow oily intermediate I with a purity of 92%.
[0105] (2) Synthesis of Intermediate II:
[0106]
[0107] Wherein, R1 is selected from ethyl.
[0108] Add intermediate I (5.0 g, 23.6 mmol), toluene (15 mL), and ethyl chloroacetate (3.76 g, 30.66 mmol) to a 100 mL three-necked flask, replace with nitrogen, and cool to 0-10 ° C; weigh sodium ethoxide (2.08 g, 30.66 mmol) and dissolve it in anhydrous ethanol (7.5 mL) to obtain a sodium ethoxide solution; drip the sodium ethoxide solution into the reaction solution while controlling the temperature of the reaction solution to 0-10 ° C. After dripping, continue stirring at 0-10 ° C for 1 h, slowly heat to 25-35 ° C, stir and react for 6 h, add toluene (15 mL) and stir after the reaction is completed; slowly drip NaOH aqueous solution (1.22 g hydroxyl radical) into the reaction solution; Sodium hydroxide was dissolved in 2.5 mL of water), and after the addition, the temperature was raised to 30-40°C and stirring was continued for 1 h; after the reaction was completed, stirring was stopped, the liquid was allowed to stand for separation, and the aqueous phase was retained; 30 mL of toluene was added to the aqueous phase and stirred for 15-20 min, stirring was stopped, the liquid was allowed to stand for separation, and the aqueous phase was retained; 30 mL of toluene was added to the aqueous phase and stirred, concentrated hydrochloric acid (3.15 mL, 37 wt%, 37.65 mmol) was slowly added, and the temperature was raised to 90-100°C and stirred for 4 h; after the reaction was completed, the temperature was lowered to 20-30°C, the liquid was separated, and the organic phase was retained; the organic phase was washed with saturated brine (30 mL) and saturated brine (30 mL), respectively, and the organic phase was concentrated to dryness to obtain 4.74 g of light yellow oily intermediate II (yield of about 88%, directly used in the next step reaction) with a purity of 93%.
[0109] (3) Synthesis of Fenoprofen:
[0110]
[0111] Add intermediate II (5.0 g, 22.1 mmol), hydroxylamine hydrochloride (2.76 g, 39.72 mmol), sodium carbonate (4.21 g, 39.72 mmol) and 50 mL of water to a 100 mL three-necked flask and stir at 20-30 ° C for 2 h; after the reaction is completed, add ethyl acetate (30 mL) to the reaction solution, stir for 15-20 min, stop stirring, stand for separation, and retain the organic phase; add ethyl acetate (30 mL) to the aqueous phase, stir for 15-20 min, stop stirring, stand for separation, and retain the organic phase; combine the organic phases, concentrate to dryness under reduced pressure, and add potassium hydroxide aqueous solution (9 .90g potassium hydroxide is dissolved in 9.9mL water), after nitrogen replacement, the temperature is raised to 110-120°C and stirred for reaction for 8h; the temperature is lowered to 20-30°C, the reaction solution is extracted with ethyl acetate 3 times (30mL×3), and the aqueous phase is retained; the pH of the aqueous phase is adjusted to 6.0-7.0 with 4mol / L dilute hydrochloric acid, 30mL ethyl acetate is added to the reaction solution, stirred for 15-20min, the stirring is stopped, the liquid is allowed to stand, and the organic phase is retained; the organic phase is washed with saturated brine (30mL) and saturated brine (30mL), respectively, and the organic phase is concentrated to dryness to obtain 4.76g of light yellow oily fenoprofen (yield of about 89%) with a purity of 94%.
[0112] The present invention provides a method and idea for preparing fenoprofen. There are many methods and approaches to realize the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the protection scope of the present invention. All components not specified in this embodiment can be realized by existing technologies.
Claims
1. A method for preparing fenoprofen, characterized in that: Intermediate II undergoes oximation reaction with hydroxylamine hydrochloride under the action of base E, and then undergoes hydrolysis reaction under the action of base F to obtain fenoprofen; 2. A method for preparing fenoprofen, characterized in that: The steps include: (I) 3-Hydroxyacetophenone and bromobenzene undergo a substitution reaction under the action of a catalyst, a base A, and a ligand to obtain an intermediate I; (II) Intermediate I and a halogenated acetic acid ester derivative undergo a Darwin condensation reaction under the action of a base C, and then undergo an ester bond hydrolysis reaction under the action of a base D, and then undergo a decarboxylation reaction under the action of an acid B to obtain an intermediate II; (III) Intermediate II undergoes an oximation reaction with hydroxylamine hydrochloride under the action of base E, and then undergoes a hydrolysis reaction under the action of base F to obtain fenoprofen; Wherein, R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl; X is selected from Br or Cl.
3. A method for preparing intermediate I, characterized in that: 3-Hydroxyacetophenone and bromobenzene undergo a substitution reaction under the action of a catalyst, a base A, and a ligand to obtain an intermediate I; 4. A method for preparing intermediate II, characterized in that: Intermediate I undergoes Darwin condensation reaction with a halogenated acetic acid ester derivative under the action of base C, and then undergoes ester bond hydrolysis reaction under the action of base D, and then undergoes decarboxylation reaction under the action of acid B to obtain intermediate II; Wherein, R1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl or tert-butyl; X is selected from Br or Cl.
5. The preparation method according to claim 1 or the preparation method according to claim 2, characterized in that: The molar ratio of the intermediate II to hydroxylamine hydrochloride is 1:1.0-3.0, preferably 1:1.2-2.0, and more preferably 1:1.5-1.8; the base E is sodium carbonate, potassium carbonate or cesium carbonate, preferably sodium carbonate; the molar ratio of the intermediate II to the base E is 1:1.0-3.0, preferably 1:1.2-2.0, and more preferably 1:1.5-1.8; the reaction temperature of the oximation reaction is 15-35°C, preferably 18 ~35℃, more preferably 20~30℃; the base F is any one of sodium hydroxide and potassium hydroxide or a combination of two, preferably potassium hydroxide; the molar ratio of the intermediate II to the base F is 1:5.0~10.0, preferably 1:6.0~9.0, more preferably 1:7.0~8.0; the hydrolysis reaction, the reaction temperature is 105~125℃, preferably 110~120℃; the hydrolysis reaction is carried out under the protection of inert gas.
6. The preparation method according to claim 1 or the preparation method according to claim 2, characterized in that: The fifth solvent used in the oximation reaction is water; the base F exists in the form of a solution, and the base F is mixed with water to prepare a base F solution.
7. The preparation method according to claim 2 or the preparation method according to claim 3, characterized in that: The molar ratio of the 3-hydroxyacetophenone to bromobenzene is 1:0.8-1.2, preferably 1:0.90-1.1, and more preferably 1:0.95-1.0; the catalyst is cuprous chloride, cuprous bromide or cuprous iodide, preferably cuprous iodide; the base A is sodium carbonate, potassium carbonate or cesium carbonate, preferably cesium carbonate; the ligand is 8-hydroxyquinoline, 1,10-phenanthroline, 2-aminopyridine, 2,2'-bipyridylamine, preferably 2,2'-bipyridylamine; the 3-hydroxyacetophenone and the catalyst are The molar ratio of the activating agent is 1:0.05-0.2, preferably 1:0.1-0.15; the molar ratio of the 3-hydroxyacetophenone to the base A is 1:1.5-3.0, preferably 1:2.0-2.5; the molar ratio of the 3-hydroxyacetophenone to the ligand is 1:0.1-0.4, preferably 1:0.2-0.3; the reaction temperature of the substitution reaction is 80-140°C, preferably 90-120°C, and more preferably 100-110°C; the substitution reaction is carried out under the protection of an inert gas.
8. The preparation method according to claim 2 or the preparation method according to claim 3, characterized in that: The first solvent used in the substitution reaction is dimethyl sulfoxide, NN-dimethylformamide, N-methylpyrrolidone, 1,4-dioxane, preferably 1,4-dioxane; after the substitution reaction is completed, the reaction solution is filtered, the filter cake is washed with a second solvent, and the filtrate is washed with an alkali B solution and an acid A solution; the second solvent is ethyl acetate, isopropyl acetate, dichloromethane, methyl tert-butyl ether, n-heptane, preferably ethyl acetate; the alkali B solution is a sodium hydroxide solution; the acid A solution is a hydrochloric acid solution.
9. The preparation method according to claim 2 or the preparation method according to claim 4, characterized in that: The halogenated acetate derivative is ethyl chloroacetate, methyl chloroacetate, n-propyl chloroacetate, isopropyl chloroacetate, n-butyl chloroacetate or tert-butyl chloroacetate, preferably ethyl chloroacetate; the molar ratio of the intermediate I to the halogenated acetate derivative is 1:1.0-1.5, preferably 1:1.1-1.4, and more preferably 1:1.2-1.3; the base C is any one or a combination of two of sodium methoxide, potassium methoxide, sodium ethoxide, potassium ethoxide, sodium isopropoxide, potassium isopropoxide, sodium tert-butoxide and potassium tert-butoxide, preferably sodium ethoxide; the molar ratio of the intermediate I to the base C is 1:1.0-1.5, preferably 1:1.1-1.4, and more preferably 1:1.2-1.3; the Darcun condensation reaction, the reaction temperature is 0 ~35℃, preferably 0~30℃; the Darcuns condensation reaction is carried out under the protection of inert gas; the base D is any one of sodium hydroxide and potassium hydroxide or a combination of two, preferably sodium hydroxide; the molar ratio of the intermediate I to the base D is 1:1.0~1.5, preferably 1:1.1~1.4, and more preferably 1:1.2~1.3; the ester bond hydrolysis reaction, the reaction temperature is 25~45℃, preferably 30~40℃; the acid B is concentrated hydrochloric acid or concentrated sulfuric acid, preferably concentrated hydrochloric acid; the molar ratio of the intermediate I to the acid B is 1:1.2~2.0, preferably 1:1.3~1.8, and more preferably 1:1.5~1.6; the decarboxylation reaction, the reaction temperature is 80~100℃, preferably 85~95℃.
10. The preparation method according to claim 2 or the preparation method according to claim 4, characterized in that: The third solvent used in the Darcuns condensation reaction is any one or a combination of toluene, ethyl acetate, isopropyl acetate, dichloromethane and methyl tert-butyl ether, preferably toluene; the base C exists in the form of a solution, and the base C is mixed with the fourth solvent to obtain a base C solution; the base D exists in the form of a solution, and the base D is mixed with water to obtain a base D solution; the acid B exists in the form of a solution, and the acid B is mixed with water to obtain an acid B solution; the fourth solvent is any one or a combination of anhydrous methanol, anhydrous ethanol, anhydrous isopropanol and anhydrous tert-butyl alcohol, preferably anhydrous ethanol.
